omeprazole has been researched along with Diarrhea in 48 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "05) lower percentages of days and nights with heartburn, less pain severity of both day and night heartburn, fewer days of antacid use, and smaller amounts of antacid use compared with patients who were treated with ranitidine or placebo." | 9.09 | Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. ( Campbell, DR; Fludas, C; Huang, B; Kahrilas, PJ; Richter, JE, 2000) |
| "To compare the healing rates of acute duodenal ulcer in patients receiving pantoprazole 40 mg or omeprazole 20 mg once daily and to assess drug tolerance." | 9.08 | Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer. ( Beker, JA; Bianchi Porro, G; Bigard, MA; Delle Fave, G; Devis, G; Gouerou, H; Maier, C, 1995) |
| " The present study was designed to test the hypothesis that a triple therapy with pantoprazole, clarithromycin and amoxycillin cures the infection in > or = 80% of duodenal ulcer patients infected with H." | 9.08 | Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. ( Labenz, J; Lütke, A; Stolte, M; Tillenburg, B; Weismüller, J, 1997) |
| "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease." | 7.73 | Lansoprazole-associated collagenous colitis: a case report. ( Höbling, W; Kirchgatterer, A; Knoflach, P; Rammer, M, 2005) |
| "A case of severe diarrhea and hypergastrinemia after 6 wk of lansoprazole therapy is presented." | 7.70 | Lansoprazole: a cause of secretory diarrhea. ( Goff, JS, 1998) |
| "We report two cases of lymphocytic colitis with severe diarrhea in patients treated by lansoprazole for six weeks." | 7.70 | [lymphocytic colitis associated with lansoprazole treatment]. ( De Maeght, S; Gerard, R; Ghilain, JM; Henrion, J; Maisin, JM; Piron, A; Schapira, M, 2000) |
| "Lansoprazole is a proton pump inhibitor widely prescribed for gastroesophageal reflux and benign peptic ulcer disease." | 5.32 | Diarrhea associated with lansoprazole. ( Mukherjee, S, 2003) |
| "Lansoprazole is a potent proton pump inhibitor that has been well tolerated with minimal serious adverse events." | 5.31 | Lansoprazole-associated microscopic colitis: a case series. ( Bensen, SP; Lestina, LS; Maheshwari, Y; Ratcliffe, NR; Thomson, RD; Toor, A, 2002) |
| "Five patients with gastroesophageal reflux disease (GERD), who also had chronic functional diarrhea and postprandial urgency, unexpectedly noted rapid relief of their diarrhea and urgency when they took lansoprazole for their heartburn." | 5.09 | Inhibition of gastric secretion relieves diarrhea and postprandial urgency associated with irritable bowel syndrome or functional diarrhea. ( Dave, B; Rubin, W, 1999) |
| "05) lower percentages of days and nights with heartburn, less pain severity of both day and night heartburn, fewer days of antacid use, and smaller amounts of antacid use compared with patients who were treated with ranitidine or placebo." | 5.09 | Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. ( Campbell, DR; Fludas, C; Huang, B; Kahrilas, PJ; Richter, JE, 2000) |
| "To compare the healing rates of acute duodenal ulcer in patients receiving pantoprazole 40 mg or omeprazole 20 mg once daily and to assess drug tolerance." | 5.08 | Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer. ( Beker, JA; Bianchi Porro, G; Bigard, MA; Delle Fave, G; Devis, G; Gouerou, H; Maier, C, 1995) |
| " The present study was designed to test the hypothesis that a triple therapy with pantoprazole, clarithromycin and amoxycillin cures the infection in > or = 80% of duodenal ulcer patients infected with H." | 5.08 | Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. ( Labenz, J; Lütke, A; Stolte, M; Tillenburg, B; Weismüller, J, 1997) |
| " pylori-infected patients with endoscopically documented duodenal ulcer either currently or within the past year were randomized to 14 days of (1) lansoprazole, 30 mg bid, plus amoxicillin, 1 gm tid; (2) lansoprazole, 30 mg tid, plus amoxicillin, 1 gm tid; (3) lansoprazole, 30 mg tid alone; or (4) amoxicillin, 1 gm tid alone." | 5.08 | Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection. ( Arora, A; Graham, D; Haber, M; Harford, W; Lanza, F; Rose, P; Siepman, N; Weissfeld, A, 1996) |
| " pylori-positive peptic ulcer received lansoprazole 30 mg twice daily in combination with metronidazole 400 mg twice daily and clarithromycin 250 mg twice daily for 5 days." | 5.08 | Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? ( Cunnane, K; Kelly, S; Laundon, J; McLoughlin, R; O'Connor, HJ, 1998) |
| "One hundred and three consecutive patients with peptic ulcer disease and antral biopsies containing Helicobacter pylori were given a 7-day course of treatment with bismuth (tripotassium dicitrato bismuthate chelate) 120 mg q." | 5.08 | Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication. ( Scott, BB, 1998) |
| " The most common adverse events of headache, diarrhea, and nausea have been reported in fewer than 5% of patients treated with lansoprazole or omeprazole." | 4.80 | Safety profile of the proton-pump inhibitors. ( Reilly, JP, 1999) |
| " Adverse events that occurred significantly more often in the first month of treatment with esomeprazole compared with months 2-6 included diarrhoea, nausea/vomiting, abdominal pain, dyspepsia, headache/migraine, intolerance, malaise/lassitude, pruritus, unspecified adverse effects and abnormal sensation." | 3.74 | Safety profile of esomeprazole: results of a prescription-event monitoring study of 11 595 patients in England. ( Davies, M; Shakir, SA; Wilton, LV, 2008) |
| "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease." | 3.73 | Lansoprazole-associated collagenous colitis: a case report. ( Höbling, W; Kirchgatterer, A; Knoflach, P; Rammer, M, 2005) |
| "A case of severe diarrhea and hypergastrinemia after 6 wk of lansoprazole therapy is presented." | 3.70 | Lansoprazole: a cause of secretory diarrhea. ( Goff, JS, 1998) |
| "We report two cases of lymphocytic colitis with severe diarrhea in patients treated by lansoprazole for six weeks." | 3.70 | [lymphocytic colitis associated with lansoprazole treatment]. ( De Maeght, S; Gerard, R; Ghilain, JM; Henrion, J; Maisin, JM; Piron, A; Schapira, M, 2000) |
| "Diarrhea was common (8/20 omeprazole, 5/17 placebo), hematochezia was rare (1/20 omeprazole, 1/17 placebo); melena was not observed." | 3.30 | Double-blinded placebo-controlled clinical trial of prophylactic omeprazole in dogs treated surgically for acute thoracolumbar intervertebral disc extrusion. ( Guadiano, P; Lewis, MJ; Mehra, JM; Moore, GE; Steiner, JM; Tolbert, MK, 2023) |
| " In the presence of omeprazole, nelfinavir area under the concentration-time curve over the dosing interval (AUC(tau)), maximum observed plasma concentration (C(max)), and minimum observed plasma concentration (C(min)) were reduced by an average of 36%, 37%, and 39%, respectively, relative to administration of nelfinavir alone." | 2.73 | Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects. ( Crownover, PH; Damle, BD; Fang, AF; Glue, PW; Hewlett, D; LaBadie, RR, 2008) |
| "Forty of the patients with ESRD (50%) and 48 patients in the control group (60%) were proven to be infected with H pylori." | 2.70 | Noninvasive stool antigen assay can effectively screen Helicobacter pylori Infection and assess success of eradication therapy in hemodialysis patients. ( Huang, JJ; Sheu, BS; Wang, YL; Yang, HB, 2001) |
| "Rabeprazole is a new proton pump inhibitor with more potent acid suppressive and anti-Helicobacter effects." | 2.70 | Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. ( Fung, FM; Hu, WH; Hui, CK; Hung, WK; Lai, KC; Lam, SK; Lau, P; Li, KF; Szeto, ML; Tong, TS; Wong, BC; Wong, WM; Yee, YK; Yip, AW; Yuen, MF, 2001) |
| "Metronidazole resistance was induced in 8 out of 16 with a sensitive strain." | 2.68 | One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection. ( de Boer, WA; Ouwehand, ME; Schade, RW; Schneeberger, PM; Tytgat, GN; van Etten, RJ; van Unnik, AJ, 1997) |
| "The gastrinoma was present in a lymph node close to the greater curvature of the stomach." | 1.37 | Long-term follow-up of a child with primary lymph node gastrinoma and Zollinger-Ellison syndrome. ( Nazir, Z, 2011) |
| "Lansoprazole is a proton pump inhibitor widely prescribed for gastroesophageal reflux and benign peptic ulcer disease." | 1.32 | Diarrhea associated with lansoprazole. ( Mukherjee, S, 2003) |
| "Lansoprazole is a potent proton pump inhibitor that has been well tolerated with minimal serious adverse events." | 1.31 | Lansoprazole-associated microscopic colitis: a case series. ( Bensen, SP; Lestina, LS; Maheshwari, Y; Ratcliffe, NR; Thomson, RD; Toor, A, 2002) |
| "To estimate the rates of common adverse events in patients treated with the proton pump inhibitors omeprazole, lansoprazole and pantoprazole in general practice in England." | 1.31 | The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. ( Dunn, NR; Freemantle, S; Martin, RM; Shakir, S, 2000) |
| "Lansoprazole was mostly prescribed in patients with reflux oesophagitis (55." | 1.30 | A prospective follow-up study of 5669 users of lansoprazole in daily practice. ( Claessens, A; Heerdink, E; Lamers, CB; Leufkens, H; van Eijk, J, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.08) | 18.7374 |
| 1990's | 15 (31.25) | 18.2507 |
| 2000's | 22 (45.83) | 29.6817 |
| 2010's | 9 (18.75) | 24.3611 |
| 2020's | 1 (2.08) | 2.80 |
| Authors | Studies |
|---|---|
| Mehra, JM | 1 |
| Tolbert, MK | 1 |
| Guadiano, P | 1 |
| Steiner, JM | 1 |
| Moore, GE | 1 |
| Lewis, MJ | 1 |
| Lambert, D | 1 |
| Rouger, C | 1 |
| Diebold, MD | 1 |
| Ramaholimihaso, F | 1 |
| Boulagnon, C | 1 |
| Nguyen, Y | 1 |
| Hentzien, M | 1 |
| Jaussaud, R | 1 |
| Bani-Sadr, F | 1 |
| Abou Ziki, MD | 1 |
| Verjee, MA | 1 |
| Wei, L | 1 |
| Ratnayake, L | 1 |
| Phillips, G | 1 |
| McGuigan, CC | 1 |
| Morant, SV | 1 |
| Flynn, RW | 1 |
| Mackenzie, IS | 1 |
| MacDonald, TM | 1 |
| Kreft, B | 1 |
| Oehme, A | 1 |
| Lübbert, C | 1 |
| Marsch, WC | 1 |
| Kekulé, AS | 1 |
| Pieroni, KP | 1 |
| Bass, D | 1 |
| Nazir, Z | 1 |
| Choi, KH | 1 |
| Chung, WC | 1 |
| Lee, KM | 1 |
| Paik, CN | 1 |
| Kim, EJ | 1 |
| Kang, BK | 1 |
| Oak, JH | 1 |
| Jung, SH | 1 |
| Furr, M | 1 |
| Cohen, ND | 1 |
| Axon, JE | 1 |
| Sanchez, LC | 1 |
| Pantaleon, L | 1 |
| Haggett, E | 1 |
| Campbell, R | 1 |
| Tennent-Brown, B | 1 |
| Kloesel, B | 1 |
| Chandan, VS | 1 |
| Alexander, GL | 1 |
| Thomson, RD | 1 |
| Lestina, LS | 1 |
| Bensen, SP | 1 |
| Toor, A | 1 |
| Maheshwari, Y | 1 |
| Ratcliffe, NR | 1 |
| Claessens, AA | 1 |
| Heerdink, ER | 1 |
| van Eijk, JT | 1 |
| Lamers, CB | 2 |
| Leufkens, HG | 1 |
| Mukherjee, S | 1 |
| Blonski, WC | 1 |
| Katzka, DA | 1 |
| Lichtenstein, GR | 1 |
| Metz, DC | 1 |
| Rammer, M | 1 |
| Kirchgatterer, A | 1 |
| Höbling, W | 1 |
| Knoflach, P | 1 |
| Hilmer, SN | 1 |
| Heap, TR | 1 |
| Eckstein, RP | 1 |
| Lauer, CS | 1 |
| Shenfield, GM | 1 |
| Stämpfli, H | 1 |
| Oliver, OE | 1 |
| Hassall, E | 1 |
| Kerr, W | 1 |
| El-Serag, HB | 1 |
| Fang, AF | 1 |
| Damle, BD | 1 |
| LaBadie, RR | 1 |
| Crownover, PH | 1 |
| Hewlett, D | 1 |
| Glue, PW | 1 |
| Davies, M | 1 |
| Wilton, LV | 1 |
| Shakir, SA | 1 |
| Becker, HD | 1 |
| Beker, JA | 1 |
| Bianchi Porro, G | 1 |
| Bigard, MA | 1 |
| Delle Fave, G | 1 |
| Devis, G | 1 |
| Gouerou, H | 1 |
| Maier, C | 1 |
| Pallarés Manrique, H | 1 |
| García Montes, MJ | 1 |
| Díaz Cano, S | 1 |
| Barranco Jiménez, M | 1 |
| Delgado Bellido, D | 1 |
| Herrerías Gutiérrez, JM | 1 |
| Gough, AL | 1 |
| Long, RG | 1 |
| Cooper, BT | 1 |
| Fosters, CS | 1 |
| Garrett, AD | 1 |
| Langworthy, CH | 1 |
| Aichbichler, BW | 1 |
| Zerr, CH | 1 |
| Santa Ana, CA | 1 |
| Porter, JL | 1 |
| Fordtran, JS | 1 |
| Labenz, J | 1 |
| Tillenburg, B | 1 |
| Weismüller, J | 1 |
| Lütke, A | 1 |
| Stolte, M | 1 |
| de Boer, WA | 1 |
| van Etten, RJ | 1 |
| Schade, RW | 1 |
| Ouwehand, ME | 1 |
| Schneeberger, PM | 1 |
| van Unnik, AJ | 1 |
| Tytgat, GN | 1 |
| Leufkens, H | 1 |
| Claessens, A | 1 |
| Heerdink, E | 1 |
| van Eijk, J | 1 |
| Harford, W | 1 |
| Lanza, F | 1 |
| Arora, A | 1 |
| Graham, D | 1 |
| Haber, M | 2 |
| Weissfeld, A | 2 |
| Rose, P | 2 |
| Siepman, N | 2 |
| Schwartz, H | 1 |
| Krause, R | 1 |
| Kidd, S | 1 |
| Sahba, B | 1 |
| Tan, AC | 1 |
| den Hartog, G | 1 |
| Meijer, JW | 1 |
| Thies, JE | 1 |
| de Vries, RA | 1 |
| Mulder, CJ | 1 |
| O'Connor, HJ | 1 |
| McLoughlin, R | 1 |
| Kelly, S | 1 |
| Laundon, J | 1 |
| Cunnane, K | 1 |
| Scott, BB | 1 |
| Goff, JS | 1 |
| Dave, B | 1 |
| Rubin, W | 1 |
| Reilly, JP | 1 |
| Dammann, HG | 1 |
| Fölsch, UR | 1 |
| Hahn, EG | 1 |
| von Kleist, DH | 1 |
| Klör, HU | 1 |
| Kirchner, T | 1 |
| Strobel, S | 1 |
| Kist, M | 1 |
| Calvet, X | 1 |
| Titó, L | 1 |
| Comet, R | 1 |
| García, N | 1 |
| Campo, R | 1 |
| Brullet, E | 1 |
| Richter, JE | 1 |
| Campbell, DR | 1 |
| Kahrilas, PJ | 1 |
| Huang, B | 1 |
| Fludas, C | 1 |
| Martin, RM | 1 |
| Dunn, NR | 1 |
| Freemantle, S | 1 |
| Shakir, S | 1 |
| Ghilain, JM | 1 |
| Schapira, M | 1 |
| Maisin, JM | 1 |
| De Maeght, S | 1 |
| Piron, A | 1 |
| Gerard, R | 1 |
| Henrion, J | 1 |
| Armuzzi, A | 1 |
| Cremonini, F | 1 |
| Ojetti, V | 1 |
| Bartolozzi, F | 1 |
| Canducci, F | 1 |
| Candelli, M | 1 |
| Santarelli, L | 1 |
| Cammarota, G | 1 |
| De Lorenzo, A | 1 |
| Pola, P | 1 |
| Gasbarrini, G | 1 |
| Gasbarrini, A | 1 |
| Baede-van Dijk, PA | 1 |
| Hugen, PW | 1 |
| Verweij-van Wissen, CP | 1 |
| Koopmans, PP | 1 |
| Burger, DM | 1 |
| Hekster, YA | 1 |
| Wang, YL | 1 |
| Sheu, BS | 1 |
| Huang, JJ | 1 |
| Yang, HB | 1 |
| Lau, CF | 1 |
| Hui, PK | 1 |
| Fung, TT | 1 |
| Tung, SY | 1 |
| Wong, AM | 1 |
| Loo, CK | 1 |
| Lam, KM | 1 |
| Wong, BC | 1 |
| Wong, WM | 1 |
| Yee, YK | 1 |
| Hung, WK | 1 |
| Yip, AW | 1 |
| Szeto, ML | 1 |
| Li, KF | 1 |
| Lau, P | 1 |
| Fung, FM | 1 |
| Tong, TS | 1 |
| Lai, KC | 1 |
| Hu, WH | 1 |
| Yuen, MF | 1 |
| Hui, CK | 1 |
| Lam, SK | 1 |
| Narayani, RI | 1 |
| Burton, MP | 1 |
| Young, GS | 1 |
| Miwa, H | 1 |
| Kurosawa, A | 1 |
| Sato, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice[NCT01273441] | Phase 4 | 338 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for omeprazole and Diarrhea
| Article | Year |
|---|---|
Idiopathic gastric acid hypersecretion presenting as a diarrheal disorder and mimicking both Zollinger-Ellison syndrome and Crohn's disease.
Topics: Adult; Anti-Ulcer Agents; Crohn Disease; Diagnosis, Differential; Diarrhea; Female; Gastric Acid; Ga | 2005 |
[Zollinger-Ellison syndrome].
Topics: Benzimidazoles; Calcium; Cimetidine; Diarrhea; Duodenal Ulcer; Female; Fluorouracil; Gastrectomy; Ga | 1984 |
Safety profile of the proton-pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Diarrhea; Drug Interactions; Gastric Muc | 1999 |
[Adverse effects of H. pylori eradication therapy and its measure].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Clarithromycin; Diarrhea; Drug Therap | 2002 |
20 trials available for omeprazole and Diarrhea
| Article | Year |
|---|---|
Double-blinded placebo-controlled clinical trial of prophylactic omeprazole in dogs treated surgically for acute thoracolumbar intervertebral disc extrusion.
Topics: Animals; Diarrhea; Dog Diseases; Dogs; Gastrointestinal Hemorrhage; Intervertebral Disc; Interverteb | 2023 |
Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Diarrhea; Double-Blind Method; Drug | 2011 |
Significant decrease in nelfinavir systemic exposure after omeprazole coadministration in healthy subjects.
Topics: Adolescent; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Li | 2008 |
Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; | 1995 |
Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Diarrhea; Double-Blind Method; Enzyme Inhibitors; Esophagit | 1996 |
Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 1997 |
One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1997 |
Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Diar | 1996 |
Seven-day triple therapy with lansoprazole, clarithromycin, and metronidazole for the cure of Helicobacter pylori infection: a short report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Clarithromycin; Diarrhea; Drug Administration | 1996 |
No additional value of bismuth subcitrate to combination omeprazole/amoxicillin therapy in the eradication of Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Atrophy; Biopsy; Data Interpreta | 1997 |
Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial | 1998 |
Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; | 1998 |
Inhibition of gastric secretion relieves diarrhea and postprandial urgency associated with irritable bowel syndrome or functional diarrhea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Chronic Disease; Colonic Disea | 1999 |
Eradication of H. pylori with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Aged; Anti-Bacterial Agents; Anti-Ul | 2000 |
Four-day, twice daily, quadruple therapy with amoxicillin, clarithromycin, tinidazole and omeprazole to cure Helicobacter pylori infection: a pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diarrhea; Drug A | 2000 |
Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Aged; Aged, 80 and over; Antacids; A | 2000 |
Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidaz | 2001 |
Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients.
Topics: Adolescent; Adult; Age Factors; Aged; Aryl Hydrocarbon Hydroxylases; Body Weight; Cytochrome P-450 C | 2001 |
Noninvasive stool antigen assay can effectively screen Helicobacter pylori Infection and assess success of eradication therapy in hemodialysis patients.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, Bacterial; Antigens, | 2001 |
Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2001 |
24 other studies available for omeprazole and Diarrhea
| Article | Year |
|---|---|
Gastritis due to Helicobacter pylori, an unusual cause of chronic diarrhoea in HIV infected patients.
Topics: Aged; Amoxicillin; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breath Tests; Chronic Dis | 2014 |
Rare mutation in the SLC26A3 transporter causes life-long diarrhoea with metabolic alkalosis.
Topics: Adult; Alkalosis; Bicarbonates; Chloride-Bicarbonate Antiporters; Chlorides; Diarrhea; Female; Human | 2015 |
Acid-suppression medications and bacterial gastroenteritis: a population-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Infections; Child; Child, Preschool; Cohort St | 2017 |
[37-year old patient with fever, diarrhea and lymphadenopathy].
Topics: Adult; AIDS Serodiagnosis; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Antifungal | 2010 |
Proton pump inhibitor treatment for congenital chloride diarrhea.
Topics: Adult; Amniotic Fluid; Betamethasone; Chloride-Bicarbonate Antiporters; Delivery, Obstetric; Diarrhe | 2011 |
Long-term follow-up of a child with primary lymph node gastrinoma and Zollinger-Ellison syndrome.
Topics: Abdominal Pain; Anti-Ulcer Agents; Child; Combined Modality Therapy; Diarrhea; Duodenal Ulcer; Follo | 2011 |
Treatment with histamine-type 2 receptor antagonists and omeprazole increase the risk of diarrhoea in neonatal foals treated in intensive care units.
Topics: Animals; Animals, Newborn; Anti-Ulcer Agents; Clostridium Infections; Diarrhea; Female; Histamine H2 | 2012 |
An unusual referral for epigastric pain, nausea, abdominal bloating, diarrhea, and weight loss.
Topics: Abdominal Pain; Adult; Anti-Ulcer Agents; Biopsy; Celiac Disease; Diarrhea; Diet, Gluten-Free; Duode | 2012 |
Lansoprazole-associated microscopic colitis: a case series.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Colitis; Co | 2002 |
Characteristics of diarrhoea in 10,008 users of lansoprazole in daily practice: which co-factors contribute?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Infective Agents; Child; Chil | 2002 |
Diarrhea associated with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Colitis; Colonoscopy; Diarrhea; Gastroin | 2003 |
Lansoprazole-associated collagenous colitis: a case report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Biopsy; Colitis; Collagen; Colonoscopy; Diagnosis, Differen | 2005 |
Microscopic colitis associated with exposure to lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Biopsy; Chronic Disease; Colitis, Collagenous; Coliti | 2006 |
Chronic diarrhea and weight loss in three horses.
Topics: Animals; Anti-Ulcer Agents; Desulfovibrionaceae Infections; Diarrhea; Endoscopy, Gastrointestinal; E | 2006 |
Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Distribution; Child; Child, Preschool; Cohort Studies; | 2007 |
Safety profile of esomeprazole: results of a prescription-event monitoring study of 11 595 patients in England.
Topics: Adverse Drug Reaction Reporting Systems; Cohort Studies; Diarrhea; Drug Monitoring; Dyspepsia; Engla | 2008 |
[Collagenous colitis].
Topics: Adrenal Cortex Hormones; Adult; Colitis; Collagen Diseases; Diarrhea; Female; Humans; Middle Aged; O | 1993 |
Proton-pump inhibition of gastric chloride secretion in congenital chloridorrhea.
Topics: Adult; Chlorides; Chronic Disease; Diarrhea; Feces; Gastric Mucosa; Humans; Hypokalemia; Intestinal | 1997 |
A prospective follow-up study of 5669 users of lansoprazole in daily practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 1997 |
Lansoprazole: a cause of secretory diarrhea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Diarrhea; Femal | 1998 |
The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Adverse Drug Reaction Reporting Syst | 2000 |
[lymphocytic colitis associated with lansoprazole treatment].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Colitis; Diarrhea; Humans; Intestinal Mu | 2000 |
Pseudomembranous colitis without diarrhoea following Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents | 2001 |
Resolution of collagenous colitis after treatment for Helicobacter pylori.
Topics: Aged; Biopsy, Needle; Clarithromycin; Colitis; Collagen; Diarrhea; Drug Therapy, Combination; Female | 2002 |